Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
10X Fund, L.P., a ten percent owner of Galectin Therapeutics Inc (NASDAQ:GALT), sold 50,000 shares of common stock on October 22, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed in two separate transactions, fetching prices between $4.93 and $4.94, for a total value of $246,800. The stock, currently trading at $5.23, has seen remarkable gains this year, with a 286% year-to-date return according to InvestingPro data.
Specifically, 20,000 shares were sold at $4.93 per share, and 30,000 shares were sold at $4.94 per share.
Following these transactions, 10X Fund, L.P. directly owns 5,872,207 shares of Galectin Therapeutics.
10X Capital Management, LLC, is the general partner of 10X Fund, L.P. James C. Czirr is the manager of 10X Capital Management, LLC. All three parties have disclaimed beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.